The U.S. FDA is trying to change how drug manufacturing capacity gets built in America.
The agency has selected several companies, including Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin, for its new PreCheck pilot program. The program is designed to speed up the review of new pharmaceutical manufacturing facilities in the United States.
This is not just a regulatory experiment.
It is another sign that drug manufacturing is becoming a national supply-chain priority.
For years, the pharmaceutical industry has relied on globalized manufacturing networks. APIs, intermediates, excipients, sterile injectables, biologics and finished dosage forms have often moved across multiple countries before reaching patients.
That model lowered costs, but it also created exposure.
COVID-19, logistics disruptions, geopolitical tension and API shortages have all forced governments to rethink how much pharmaceutical production should remain overseas.
The FDA’s PreCheck program fits into that shift.
Instead of waiting until a facility is fully built and ready for inspection, the FDA wants to engage earlier in the process. The goal is to reduce delays, improve regulatory predictability and help companies bring domestic manufacturing capacity online faster.
For companies like Lilly, this matters especially because of the surge in demand for metabolic and weight-loss medicines. Lilly’s Lebanon, Indiana site is tied to production related to weight-loss tablets and injectable ingredients.
That means this program is not abstract.
It is connected to some of the highest-demand drug categories in the world.
The broader message is clear: the U.S. wants more control over where critical medicines are made.
For API and CDMO suppliers, this could create new opportunities. More domestic facilities mean more demand for compliant raw materials, process chemicals, excipients, equipment, validation services and manufacturing partnerships.
But it also raises the bar.
Companies that want to serve the U.S. pharmaceutical supply chain will need stronger documentation, cleaner audit trails, better quality systems and more reliable regulatory support.
The next phase of pharmaceutical manufacturing will not only be about cost.
It will be about speed, compliance, resilience and location strategy.
